May 4, 2023
BMS announced that Breyanzi (lisocabtagene maraleucel) met the primary endpoint of the overall response rate in two types of non-Hodgkin's lymphoma; relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Also read: Top pharmaceutical companies in 2023
TRANSCEND FL is an open-label, Phase 2, single-arm study, while TRANSCEND NHL 001 recruited patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including mantle cell lymphoma (MCL). In both trials, Breyanzi met the primary endpoint of the overall response rate and the key secondary endpoints, including the complete response rate.
BMS also announced positive results from the TRANSCEND CLL 004 trial, demonstrating the efficacy of Breyanzi in patients with chronic lymphocytic leukemia. It met the primary endpoint of a complete response rate.
Also read: China drug approvals | 2023
Follicular lymphoma is the second-most common slow-growing non-Hodgkin's lymphoma, accounting for 20-30% of all non-Hodgkin's lymphoma cases.
Mantle cell lymphoma is however an aggressive cancer, accounting for 2% of all non-Hodgkin lymphoma cases.